MARKET
IPO

GRAL

Grail, Inc.
GRAL
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
Biotechnology & Medical Research
2020-09-09
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: Pending
Listed
Illumina Says Grail Deal Won’t Hold Back New Cancer Tests
Bloomberg · 06/08 22:55
Illumina DNA-Data Security Threat Prompts Warning From FDA
Bloomberg · 06/02 18:41
Pandemic Response Lacks Strong Gene Analytics, Illumina CEO Says
Bloomberg · 04/19 16:20
Illumina Faces Battle to Save Grail Deal From EU Veto
Bloomberg · 01/26 07:14
The Close Full Show (1/12/2022)
Bloomberg · 01/13 02:58
Illumina Benefiting From Increased Access to Tests: CEO
Bloomberg · 01/12 21:30
Illumina CEO Says Increasing Access to Testing Has Lifted Sales
Bloomberg · 01/12 19:41
Illumina Fights Curbs on Grail Deal Closed Without EU Nod
Bloomberg · 12/07/2021 14:51
More
No Data
Learn about the latest financial forecast of GRAL. Analyze the recent business situations of Grail, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.17%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Chairman/Director
Catherine Friedman
Chief Executive Officer/Director
Hans Bishop
Vice Chairman/Co-Founder/Director
Jeffrey Huber
Chief Financial Officer/Chief Operating Officer/Primary Contact
Matthew Young
Director
Hal Barron
Director
Xiangmin Cui
Director
Bill Rastetter
No Data
No Data
About GRAL
GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

Webull offers kinds of Grail, Inc. stock information, including NASDAQ:GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.